# Applying Cognitive Stimulation Therapy (CST) on People with Concurrent Visual Impairment and Dementia: A Preliminary Study

**Authors:** Hiu Tung Tsang, Chun Lam Luk, Yee Lam Lo, Armstrong Tat San Chiu, Ben Chi Bun Yip, Winsy Wing Sze Wong

PMC · DOI: 10.3390/brainsci16020168 · Brain Sciences · 2026-01-30

## TL;DR

This study shows that cognitive stimulation therapy can help people with dementia and visual impairment improve their cognitive and language skills.

## Contribution

The study is the first to explore the use of CST in individuals with both dementia and visual impairment.

## Key findings

- Participants showed significant improvements in cognitive domains after CST.
- Language measures also improved following the therapy sessions.
- Treatment adherence was satisfactory among the participants.

## Abstract

Background/Objectives: This pilot study explored the applicability and preliminary clinical outcomes of cognitive stimulation therapy (CST), an evidence-based cognitive intervention for people with mild and moderate dementia, in elderly individuals with concurrent dementia and visual impairment. Methods: Seven participants received 14 group CST sessions. Their cognitive and language functions were measured and compared pre-/post-therapy. Results: The treatment adherence was satisfactory. Significant improvements in various cognitive domains and language measures were observed after therapy. Conclusions: The findings suggest that CST can be applied to visually impaired individuals with dementia with seemingly positive outcomes in various cognitive domains. Further studies with a larger sample with an emphasis on multisensory stimulation to facilitate therapy delivery are warranted.

## Linked entities

- **Diseases:** dementia (MONDO:0001627)

## Full-text entities

- **Genes:** CST12P (cystatin 12, pseudogene) [NCBI Gene 106478911] {aka Cst, Ctes4, E2}
- **Diseases:** learning disability (MESH:D007859), Dementia (MESH:D003704), sensory (MESH:D009477), PwD (MESH:C000719191), neurological diseases (MESH:D020271), cognitive deterioration (MESH:D003072), disability (MESH:D009069), memory loss (MESH:D008569), hearing impairment (MESH:D034381), frontotemporal NCD (MESH:D057180), physical illness (MESH:D059445), PwDVI (MESH:D014786), injury to (MESH:D014947), visual hallucinations (MESH:D006212), hearing and/or visual impairment (MESH:D006311), Lewy Body dementia (MESH:D020961), Alzheimer's disease (MESH:D000544), memory decline (MESH:D060825), Mental Disorders (MESH:D001523), NCDs (MESH:D019965), vascular disease (MESH:D014652)
- **Chemicals:** galantamine (MESH:D005702)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938302/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938302/full.md

---
Source: https://tomesphere.com/paper/PMC12938302